In combined studies , serious adverse events were reported in 14 ( 19 % ) of 734 patients given ixekizumab every 2 weeks , 14 ( 19 % ) of 729 given ixekizumab every 4 weeks , seven ( 19 % ) of 360 given placebo , and 14 ( 19 % ) of 739 given etanercept ; no deaths were noted .